<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3131">
  <stage>Registered</stage>
  <submitdate>28/03/2011</submitdate>
  <approvaldate>28/03/2011</approvaldate>
  <nctid>NCT01331850</nctid>
  <trial_identification>
    <studytitle>A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C</studytitle>
    <scientifictitle>A Randomized Open-label Study to Evaluate the Sustained Virologic Response of Danoprevir/Ritonavir and Copegus in Combination With RO5024048 and/or Pegasys in Chronic Hepatitis C Genotype 1 Patients Who Failed Previous Standard Therapy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2010-019585-90</secondaryid>
    <secondaryid>WV21913</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis C, Chronic</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Copegus
Treatment: drugs - Copegus
Treatment: drugs - Pegasys
Treatment: drugs - Pegasys
Treatment: drugs - RO5024048
Treatment: drugs - danoprevir
Treatment: drugs - ritonavir

Experimental: Previous null responders (Cohort B): Group 4 - Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. In addition, Group 4 will receive RO5024048 1000 mg twice a day and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.

Experimental: Previous null responders (Cohort B): Group 5 - Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. Group 5 will receive RO5024048 1000 mg twice a day, Pegasys 180 microgram subcutaneously once weekly and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.

Experimental: Previous null responders (Cohort B): Group 6 - Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. Group 6 will receive RO5024048 1000 mg twice a day, Pegasys 180 microgram subcutaneously once weekly and Copegus 1000 mg or 1200 mg twice a day for 24 weeks. In addition, patients in Group 6 will receive another 24 weeks of Pegasys plus Copegus treatment.

Experimental: Previous partial responders (Cohort A): Group 1 - Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. In addition, Group 1 will receive RO5024048 1000 mg twice a day and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.

Experimental: Previous partial responders (Cohort A): Group 2 - Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. In addition, Group 2 will receive Pegasys 180 microgram subcutaneously once weekly and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.

Experimental: Previous partial responders (Cohort A): Group 3 - Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir 100 mg twice a day for 24 weeks. Group 3 will receive RO5024048 1000 mg twice a day, Pegasys 180 microgram subcutaneously once weekly and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.


Treatment: drugs: Copegus
1000 mg or 1200 mg daily oral doses for 24 weeks

Treatment: drugs: Copegus
1000 mg or 1200 mg daily oral doses for 48 weeks

Treatment: drugs: Pegasys
180 microgram subcutaneously once weekly for 24 weeks

Treatment: drugs: Pegasys
180 microgram subcutaneously once weekly for 48 weeks

Treatment: drugs: RO5024048
1000 mg oral doses twice a day for 24 weeks

Treatment: drugs: danoprevir
100 mg oral doses twice a day for 24 weeks

Treatment: drugs: ritonavir
100 mg oral doses twice a day for 24 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Sustained virological response (SVR) of danoprevir/ritonavir with RO5024048 and Copegus in patients with previous partial or null response to peginterferon/ribavirin treatment</outcome>
      <timepoint>24 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Sustained virological response (SVR) of danoprevir/ritonavir with Pegasys and Copegus in patients with previous partial response to peginterferon/ribavirin treatment</outcome>
      <timepoint>24 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Sustained virological response (SVR) of danoprevir/ritonavir and RO5024048 with Pegasys and Copegus in patients with previous partial or null response to peginterferon/ribavirin treatment</outcome>
      <timepoint>24 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Sustained virological response (SVR) of danoprevir/ritonavir and RO5024048 with Pegasys and Copegus followed by 24 weeks of Pegasys and Copegus treatment in patients with previous null response to peginterferon/ribavirin treatment</outcome>
      <timepoint>48 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety (Incidence of adverse events) of danoprevir, RO5024048 and Copegus</outcome>
      <timepoint>48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety (Incidence of adverse events) of danoprevir, Pegasys and Copegus</outcome>
      <timepoint>48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety (Incidence of adverse events) of danoprevir, RO5024048, Pegasys and Copegus</outcome>
      <timepoint>72 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Virological response over time</outcome>
      <timepoint>48 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in danoprevir plasma concentration</outcome>
      <timepoint>24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in RO5024048 plasma concentration</outcome>
      <timepoint>24 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hepatitis C virus drug resistance profile</outcome>
      <timepoint>24 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Adult patients, age 18 years and older

          -  Presence of hepatitis C infection, genotype 1a or 1b

          -  Documentation of previous treatment failure after receiving approved doses of
             peginterferon plus ribavirin for at least 12 weeks

          -  Patients must have discontinued prior hepatitis C treatment at least 12 weeks prior to
             study start</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Infection with any hepatitis C genotype or subtype other than genotype 1a or 1b

          -  Patients with cirrhosis

          -  Patients who were discontinued from previous peginterferon plus ribavirin therapy due
             to reasons other than insufficient therapeutic response

          -  Co-infection with hepatitis B or human immunodeficiency virus (HIV)

          -  History or evidence of chronic liver disease other than hepatitis C</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>381</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,VIC</recruitmentstate>
    <hospital> - Darlinghurst</hospital>
    <hospital> - Kingswood</hospital>
    <hospital> - Westmead</hospital>
    <hospital> - Adelaide</hospital>
    <hospital> - Melbourne</hospital>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>2747 - Kingswood</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3004 - Melbourne</postcode>
    <postcode>3186 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oregon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Wien</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>RS</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>SP</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>La Tronche</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Pessac</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Vandoeuvre-les-nancy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Kiel</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>TÃ¼bingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Campania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lombardia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Toscana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Guadalajara</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bydgoszcz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Czeladz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Kielce</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>San Juan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Sevilla</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Dundee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Manchester</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Hoffmann-La Roche</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This randomized, open-label, multi-center study will evaluate the sustained virological
      response, pharmacokinetics and safety of various combinations of danoprevir/ritonavir with
      Copegus plus RO5024048 and/or Pegasys in patients with chronic hepatitis C infection.
      Patients will be divided into 2 separate cohorts. Cohort A, previous partial responders, will
      be randomized to Groups 1-3 and cohort B, previous null responders, will be randomized to
      Groups 4-6. Patients in all groups will receive danoprevir 100 mg twice a day and ritonavir
      100 mg twice a day for 24 weeks. In addition, Groups 1 and 4 will receive RO5024048 1000 mg
      twice a day and Copegus 1000 mg or 1200 mg twice a day for 24 weeks; Group 2 will receive
      Pegasys 180 microgram subcutaneously once weekly and Copegus 1000 mg or 1200 mg twice a day
      for 24 weeks; Groups 3, 5 and 6 will receive RO5024048 1000 mg twice a day, Pegasys 180
      microgram subcutaneously once weekly and Copegus 1000 mg or 1200 mg twice a day for 24 weeks.
      In addition, patients in Group 6 will receive another 24 weeks of Pegasys plus Copegus
      treatment.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01331850</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clinical Trials</name>
      <address>Hoffmann-La Roche</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>